title: Efficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study.
abstract: OBJECTIVE
  To evaluate the clinical efficacy and tolerability of propiverine and solifenacin in female patients with overactive bladder (OAB).
  
  
  METHODS
  A prospective nonrandomized crossover study of propiverine 20 mg and solifenacin 5 mg was conducted. Female OAB patients were assigned alternately to treatment with propiverine for 8 weeks then solifenacin for 8 weeks (Group P-S) or solifenacin for 8 weeks then propiverine for 8 weeks (Group S-P). At baseline, 8th week and 16th week, symptoms were assessed using overactive bladder symptom score (OABSS).
  
  
  RESULTS
  A total of 121 patients were enrolled. Overall, 38 patients (31.4%) discontinued or dropped out and 83 patients were available for analysis (39 in Group P-S and 44 in Group S-P). In both groups, the total score and each score of OABSS were significantly improved after 8 weeks compared with baseline. In only Group P-S (changing over from propiverine to solifenacin), urgency score in the 16th week was further improved significantly compared with the 8th week. The most bothersome symptom at baseline was urgency incontinence (50.6%), followed by urgency (37.3%). Even after symptom improvement, more than half of the patients were bothered by urgency or urgency incontinence. The incidence of adverse events of moderate and severe grade was higher during propiverine treatment than solifenacin (11.1% vs 2.9%, P = 0.039).
  
  
  CONCLUSIONS
  Propiverine 20 mg and solifenacin 5 mg were effective for treating female OAB patients. Urgency was further improved after switching from propiverine to solifenacin, but not after switching from solifenacin to propiverine. Solifenacin was better tolerated than propiverine.
authors.affiliation: Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, JapanDepartment of Urology, Hokkaido Social Welfare Association Furano Hospital, Furano, Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Wada
authors.affiliation: Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, JapanDepartment of Urology, Hokkaido Social Welfare Association Furano Hospital, Furano, Japan.
authors.forename: Masaki
authors.initials: M
authors.lastname: Watanabe
authors.affiliation: Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, JapanDepartment of Urology, Hokkaido Social Welfare Association Furano Hospital, Furano, Japan.
authors.forename: Masafumi
authors.initials: M
authors.lastname: Kita
authors.affiliation: Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, JapanDepartment of Urology, Hokkaido Social Welfare Association Furano Hospital, Furano, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Osanai
authors.affiliation: Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, JapanDepartment of Urology, Hokkaido Social Welfare Association Furano Hospital, Furano, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamaguchi
authors.affiliation: Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, JapanDepartment of Urology, Hokkaido Social Welfare Association Furano Hospital, Furano, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Numata
authors.affiliation: Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, JapanDepartment of Urology, Hokkaido Social Welfare Association Furano Hospital, Furano, Japan.
authors.forename: Hidehiro
authors.initials: H
authors.lastname: Kakizaki
keywords: overactive bladder; propiverine; solifenacin; urgency